TY - JOUR
T1 - Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions with Coronary Bypass Surgery
T2 - A Meta-analysis
AU - Gaudino, Mario
AU - Hameed, Irbaz
AU - Farkouh, Michael E.
AU - Rahouma, Mohamed
AU - Naik, Ajita
AU - Robinson, N. Bryce
AU - Ruan, Yongle
AU - Demetres, Michelle
AU - Biondi-Zoccai, Giuseppe
AU - Angiolillo, Dominick J.
AU - Bagiella, Emilia
AU - Charlson, Mary E.
AU - Benedetto, Umberto
AU - Ruel, Marc
AU - Taggart, David P.
AU - Girardi, Leonard N.
AU - Bhatt, Deepak L.
AU - Fremes, Stephen E.
N1 - Funding Information:
TobeSoft; as chair of the American Heart Association Quality Oversight Committee; on data monitoring committees of Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO [Macitentan for the Treatment of Portopulmonary Hypertension] trial, funded by St Jude Medical, now Abbott Laboratories), Cleveland Clinic (including for the ExCEED [Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis] trial, funded by Edwards Lifesciences), Contego Medical, LLC (chair for PERFORMANCE 2 [Protection Against Emboli During Carotid Artery Stenting Using the Neuroguard IEP System]), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE [Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation] trial, funded by Daiichi Sankyo Company, Ltd), and Population Health Research Institute; receiving honoraria from the American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org; vice-chair, American College of Cardiology Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI [Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention] clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II [CSL112 in Subjects With Acute Coronary Syndrome] executive committee funded by CSL Behring), Belvoir Publications (editor-in-chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE [Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease] trial, funded by Ferring Pharmaceuticals), HMP Global (editor-in-chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (as guest editor and associate editor), K2P (cochair of interdisciplinary curriculum), Level Ex Incorporated, Medtelligence/ReachMD (continuing medical education steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS [Cardiovascular Outcomes for People Using Anticoagulation Strategies] operations committee, publications committee, steering committee, and US national coleader, funded by Bayer AG), Slack Publications (chief medical editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (continuing medical education steering committees); serving as deputy editor of Clinical Cardiology; serving as chair of the National Cardiovascular Data Registry-ACTION Registry steering committee and chair of the Veterans Affairs Clinical Assessment, Reporting and Tracking program (research and publications committee); receiving research funding from Abbott Laboratories, Afimmune Limited, Amarin Corporation, Amgen, Inc, AstraZeneca, PLC, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Cardax, Inc, Chiesi USA, Inc, CSL Behring, Eisai Co, Ltd, Ethicon, Inc, Ferring Pharmaceuticals, Forest Laboratories, Fractyl Laboratories, Inc, Idorsia Pharmaceuticals, Ltd, Ironwood Pharmaceuticals, Inc, Ischemix, Lexicon, Eli Lilly and Company, Medtronic, Pfizer, Inc, PhaseBio Pharmaceuticals, Inc, PLx Pharma, Inc, Regeneron Pharmaceuticals, Inc, F. Hoffman-La Roche, Ltd, Sanofi Aventis, Synaptic Pharma, Ltd, and The Medicines Company; receiving royalties from Elsevier (editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); serving as site coinvestigator for Biotronik, Boston Scientific Corporation, CSI, St Jude Medical (now Abbott Laboratories), and Svelte; serving as trustee for American College of Cardiology; and performing unfunded research for FlowCo, Merck & Co, Novo Nordisk A/S, and Takeda Pharmaceutical Company Limited. No other disclosures were reported.
Funding Information:
reported receiving consulting fees or honoraria from Amgen, Inc, Aralez Pharmaceuticals, AstraZeneca, PLC, Bayer AG, Biosensors International, Ltd, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi USA, Inc, Daiichi Sankyo Company, Ltd, Eli Lilly and Company, Haemonetics Corporation, Janssen Pharmaceutica, Merck & Co, PhaseBio Pharmaceuticals, Inc, PLx Pharma, Inc, Pfizer, Inc, Sanofi SA, and The Medicines Company and payments for participation in review activities from CeloNova Biosciences, Inc, and St Jude Medical; in addition, his institution has received research grants from Amgen, Inc, AstraZeneca, PLC, Bayer AG, Biosensors International, Ltd, CeloNova Biosciences, Inc, CSL Behring, Daiichi Sankyo Company, Ltd, Eisai Co, Ltd, Eli Lilly and Company, Gilead Sciences, Inc, Idorsia Pharmaceuticals, Ltd, Janssen Pharmaceutica, Matsutani Chemical Industry Co, Ltd, Merck & Co, Novartis International AG, Osprey Medical, Inc, and RenalGuard Solutions, Inc. Dr Bhatt reported serving on the advisory boards of Cardax, Inc, CellProthera, Cereno Scientific AB, Elsevier PracticeUpdate Cardiology, Level Ex Incorporated, Medscape Cardiology, PhaseBio Pharmaceuticals, Inc, PLx Pharma, Inc, and Regado Biosciences; on the board of directors of Boston Veterans Affairs Research Institute, Society of Cardiovascular Patient Care, and
Publisher Copyright:
© 2020 American Medical Association. All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Importance: Mortality is a common outcome in trials comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG). Controversy exists regarding whether all-cause mortality or cardiac mortality is preferred as a study end point, because noncardiac mortality should be unrelated to the treatment. Objective: To evaluate the difference in all-cause and cause-specific mortality in randomized clinical trials (RCTs) comparing PCI with CABG for the treatment of patients with coronary artery disease. Data Sources: MEDLINE (1946 to the present), Embase (1974 to the present), and the Cochrane Library (1992 to the present) databases were searched on November 24, 2019. Reference lists of included articles were also searched, and additional studies were included if appropriate. Study Selection: Articles were considered for inclusion if they were in English, were RCTs comparing PCI with drug-eluting or bare-metal stents and CABG for the treatment of coronary artery disease, and reported mortality and/or cause-specific mortality. Trials of PCI involving angioplasty without stenting were excluded. For each included trial, the publication with the longest follow-up duration for each outcome was selected. Data Extraction and Synthesis: For data extraction, all studies were reviewed by 2 independent investigators, and disagreements were resolved by a third investigator in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline. Data were pooled using fixed-and random-effects models. Main Outcomes and Measures: The primary outcomes were all-cause and cause-specific (cardiac vs noncardiac) mortality. Subgroup analyses were performed for PCI trials using drug-eluting vs bare-metal stents and for trials involving patients with left main disease. Results: Twenty-three unique trials were included involving 13620 unique patients (6829 undergoing PCI and 6791 undergoing CABG; men, 39.9%-99.0% of study populations; mean age range, 60.0-71.0 years). The weighted mean (SD) follow-up was 5.3 (3.6) years. Compared with CABG, PCI was associated with a higher rate of all-cause (incidence rate ratio, 1.17; 95% CI, 1.05-1.29) and cardiac (incidence rate ratio, 1.24; 95% CI, 1.05-1.45) mortality but also noncardiac mortality (incidence rate ratio, 1.19; 95% CI, 1.00-1.41). Conclusions and Relevance: Percutaneous coronary intervention was associated with higher all-cause, cardiac, and noncardiac mortality compared with CABG at 5 years. The significantly higher noncardiac mortality associated with PCI suggests that even noncardiac deaths after PCI may be procedure related and supports the use of all-cause mortality as the end point for myocardial revascularization trials.
AB - Importance: Mortality is a common outcome in trials comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG). Controversy exists regarding whether all-cause mortality or cardiac mortality is preferred as a study end point, because noncardiac mortality should be unrelated to the treatment. Objective: To evaluate the difference in all-cause and cause-specific mortality in randomized clinical trials (RCTs) comparing PCI with CABG for the treatment of patients with coronary artery disease. Data Sources: MEDLINE (1946 to the present), Embase (1974 to the present), and the Cochrane Library (1992 to the present) databases were searched on November 24, 2019. Reference lists of included articles were also searched, and additional studies were included if appropriate. Study Selection: Articles were considered for inclusion if they were in English, were RCTs comparing PCI with drug-eluting or bare-metal stents and CABG for the treatment of coronary artery disease, and reported mortality and/or cause-specific mortality. Trials of PCI involving angioplasty without stenting were excluded. For each included trial, the publication with the longest follow-up duration for each outcome was selected. Data Extraction and Synthesis: For data extraction, all studies were reviewed by 2 independent investigators, and disagreements were resolved by a third investigator in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline. Data were pooled using fixed-and random-effects models. Main Outcomes and Measures: The primary outcomes were all-cause and cause-specific (cardiac vs noncardiac) mortality. Subgroup analyses were performed for PCI trials using drug-eluting vs bare-metal stents and for trials involving patients with left main disease. Results: Twenty-three unique trials were included involving 13620 unique patients (6829 undergoing PCI and 6791 undergoing CABG; men, 39.9%-99.0% of study populations; mean age range, 60.0-71.0 years). The weighted mean (SD) follow-up was 5.3 (3.6) years. Compared with CABG, PCI was associated with a higher rate of all-cause (incidence rate ratio, 1.17; 95% CI, 1.05-1.29) and cardiac (incidence rate ratio, 1.24; 95% CI, 1.05-1.45) mortality but also noncardiac mortality (incidence rate ratio, 1.19; 95% CI, 1.00-1.41). Conclusions and Relevance: Percutaneous coronary intervention was associated with higher all-cause, cardiac, and noncardiac mortality compared with CABG at 5 years. The significantly higher noncardiac mortality associated with PCI suggests that even noncardiac deaths after PCI may be procedure related and supports the use of all-cause mortality as the end point for myocardial revascularization trials.
UR - http://www.scopus.com/inward/record.url?scp=85093688952&partnerID=8YFLogxK
U2 - 10.1001/jamainternmed.2020.4748
DO - 10.1001/jamainternmed.2020.4748
M3 - Article
C2 - 33044497
AN - SCOPUS:85093688952
SN - 2168-6106
VL - 180
SP - 1638
EP - 1646
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
IS - 12
ER -